The anti-proliferative effects of these IMP2 inhibitor compounds on colorectal cancer and lung cancer cell lines were only partially rescued by biallelic knockout of IGF2BP2, suggesting that these compounds may have additional off-targets [85,126]. This evidence concerns the gene IGF2BP2 and lung carcinoma.